3.1.3n Triple Therapy

In this study, 400 naive patients were treated with IFN + ribavirin, and with amantadine or a placebo. “SVR was observed in 52% of the amantadine group and in 43.5% of the control group (P = .11). Among patients with HCV genotype 1 infection, the corresponding SVR rates were 39% and 31%, respectively.“ (T Berg et al. Triple therapy with amantadine in treatment-naive patients with chronic hepatitis C:Hepatology 37 (6):1359-1367. June 2003).